Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Victoria Furer, Tali Eviatar, Devy Zisman, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1330-1338
Open Access | Times Cited: 606

Showing 1-25 of 606 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, et al.
BMJ (2022), pp. e068632-e068632
Open Access | Times Cited: 390
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 384
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis
Qiao Liu, Chenyuan Qin, Min Liu, et al.
Infectious Diseases of Poverty (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 311
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
Parakkal Deepak, Wooseob Kim, Michael Paley, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 11, pp. 1572-1585
Open Access | Times Cited: 289
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Daniel Mrak, Selma Tobudic, Maximilian Koblischke, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1345-1350
Closed Access | Times Cited: 232
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
Matthias B. Moor, Franziska Suter‐Riniker, Michael P. Horn, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 11, pp. e789-e797
Open Access | Times Cited: 200
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
Ana Cristina de Medeiros Ribeiro, Nádia Emi Aikawa, Carla Gonçalves Schahin Saad, et al.
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1744-1751
Open Access | Times Cited: 175
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
Pedro Machado, Saskia Lawson‐Tovey, Anja Strangfeld, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 5, pp. 695-709
Open Access | Times Cited: 167
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
Anuraag Jena, Shubhra Mishra, Parakkal Deepak, et al.
Autoimmunity Reviews (2021) Vol. 21, Iss. 1, pp. 102927-102927
Open Access | Times Cited: 164
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
Jan‐Stephan Sanders, Fréderike J. Bemelman, A. Lianne Messchendorp, et al.
Transplantation (2021) Vol. 106, Iss. 4, pp. 821-834
Open Access | Times Cited: 161
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Rebecca Grainger, Alfred H.J. Kim, Richard Conway, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 4, pp. 191-204
Open Access | Times Cited: 159
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sebastian E. Sattui, Jean W Liew, Kevin Kennedy, et al.
RMD Open (2021) Vol. 7, Iss. 3, pp. e001814-e001814
Open Access | Times Cited: 150
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Ingrid Jyssum, Hassen Kared, Trung Tran, et al.
The Lancet Rheumatology (2021) Vol. 4, Iss. 3, pp. e177-e187
Open Access | Times Cited: 146
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 142
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS–CoV‐2 Vaccination
Peter Izmirly, Mimi Kim, Marie I. Samanovic, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 2, pp. 284-294
Open Access | Times Cited: 130
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 5, pp. e338-e350
Open Access | Times Cited: 111
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups
Clodoveo Ferri, Francesco Ursini, Laura Gragnani, et al.
Journal of Autoimmunity (2021) Vol. 125, pp. 102744-102744
Open Access | Times Cited: 109
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
Xue Li, Xinning Tong, Winnie Wan Yin Yeung, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 4, pp. 564-568
Open Access | Times Cited: 108
The RECOVAC Immune-response Study
Jan‐Stephan Sanders, Fréderike J. Bemelman, A. Lianne Messchendorp, et al.
(2021) Vol. Publish Ahead of Print
Open Access | Times Cited: 108
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study
Natacha Madelon, Kim Lauper, Gautier Bréville, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1037-e1045
Open Access | Times Cited: 107
Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review
Kin Israel Notarte, Abbygail Therese Ver, Jacqueline Veronica Velasco, et al.
Critical Reviews in Clinical Laboratory Sciences (2022) Vol. 59, Iss. 6, pp. 373-390
Open Access | Times Cited: 88
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Page 1 - Next Page

Scroll to top